CD79A and COVID-19: Thus, although the first‐generation COVID‐19 vaccines produced public benefits, such as reduction of severe infection and death in pandemic emergency situation, it is necessary to develop the next generation COVID‐19 vaccines that can induce more effective mucosal S‐IgA, in addition to systemic IgG and IgA, to achieve protection against infection and prevention of transmission of the virus.